A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs

Veterinary Dermatology

Volumn 26, Issue 1, 2015, Pages 23-e8

  Little, Peter R ^a   King, Vickie L ^a   Davis, Kylie R ^a   Cosgrove, Sallie B ^a   Stegemann, Michael R ^b  

^a ZOETIS   (United States)

^b Zoetis Veterinary Medicine Research and Development   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

CYCLOSPORIN; DERMATOLOGICAL AGENT; OCLACITINIB; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DERMATITIS, ATOPIC; DOG; DOG DISEASES; FEMALE; MALE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; VETERINARY;

ANIMALS; CYCLOSPORINE; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; FEMALE; MALE; PRURITUS; PYRIMIDINES; SINGLE-BLIND METHOD; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84921435716     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/vde.12186     Document Type: Article

References (27)

1. Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV); clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol 2001; 81: 255-269.
2. Marsella R, Sousa CA, Gonzales AJ et al. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc 2012; 241: 194-207.
3. Olivry T, DeBoer DJ, Favrot C et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010; 21: 233-248.
4. Olivry T, Foster AP, Mueller RS et al. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Vet Dermatol 2010; 21: 4-22.
5. Olivry T, Bizikova P. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update. Vet Dermatol 2013; 24: 97-117, e25-e26.
6. Atopica Product Label (Australia). Novartis Animal Health Australasia Pty Ltd, North Ryde, NSW, Australia accessed 2011.
7. Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporine for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006; 17: 3-16.
8. Burton G, Burrows A, Walker R et al. Efficacy of cyclosporin in the treatment of atopic dermatitis in dogs - combined results from two veterinary dermatology referral centres. Aust Vet J 2004; 82: 681-685.
9. Apoquel Product Label (United States). Zoetis Inc., Florham Park, NJ, USA. Available at: http://www.apoquel.com. Accessed Feb 14, 2014.
10. Apoquel Statement of Product Characteristics (European Union). Zoetis Belgium SA, Louvain-la-Neuve, Belgium. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002688/WC500152091.pdf. Accessed Feb 14, 2014.
11. Gonzales AJ, Humphrey WR, Messamore JE et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol 2013; 24: 48-53, e11-e12.
12. ®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 2014; 37: 317-324.
13. Fleck T, Humphrey W, Coscarelli E et al. Comparison of the Janus kinase (JAK) inhibitor, oclacitinib, and prednisolone in canine models of pruritus. Vet Dermatol 2012; 23(Suppl 1): 38 (abstract).
14. Cosgrove SB, Wren JA, Cleaver DM et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24: 479-e114.
15. ®) in client-owned dogs with atopic dermatitis. Vet Dermatol 2013; 24: 587-597, e141-e142.
16. International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), Good Clinical Practice, June 2000, effective 1 July 2001. Brussels, Belgium.
17. Hill PB, Lau P, Rybnicek J. Development of an owner-assessed scale to measure the severity of pruritus in dogs. Vet Dermatol 2007; 18: 301-308.
18. European Medicines Agency. Guidance notes on the use of VeDDRA terminology for reporting suspected adverse reactions in animals and humans. EMA/CVMP/PhVWP/288284/2007-Rev.6, June 2013. London, UK.
19. Olivry T, Steffan J, Fisch RD et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002; 221: 370-377.
20. ®) for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs. Vet Dermatol 2014; 25: 156 (abstract).
21. Kircik LH. Efficacy and onset of action of hydrocortisone acetate 2.5% and pramoxine hydrochloride 1% lotion for the management of pruritus: results of a pilot study. J Clin Aesthet Dermatol 2011; 4: 48-50.
22. Steffan J, Alexander D, Brovedani F et al. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol 2003; 14: 11-22.
23. Robson DC, Burton GG. Cyclosporin: applications in small animal dermatology. Vet Dermatol 2003; 14: 1-9.
24. Favrot C, Olivry T, Werner AH et al. Evaluation of papillomaviruses associated with cyclosporine-induced hyperplastic verrucous lesions in dogs. Am J Vet Res 2005; 66: 1764-1769.
25. Hillier A, Desch CE. Large-bodied Demodex mite infestation in four dogs. J Am Vet Med Assoc 2002; 220: 623-627.
26. Robson DC, Burton GG, Bassett R et al. Eight cases of demodicosis caused by a long-bodied Demodex species (1997-2002). Aust Vet Pract 2003; 33: 64-74.
27. Ordeix L, Bardagí M, Scarampella F et al. Demodex injai infestation and dorsal greasy skin and hair in eight wirehaired fox terrier dogs. Vet Dermatol 2009; 20: 267-272.